focus -WSS

focus

author：hotspot 2025-10-02 21:00:05 - browse：5

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The blockbuster weight loss and diabetes drug sold by Eli Lilly also appears to improve fatty liver disease, according to early clinical trial data the pharmaceutical company released Tuesday.

Eli Lilly reported during its fourth-quarter earnings call that tirzepatide, which is sold commercially as Mounjaro or Zepbound, succeeded in a Phase 2 test as a treatment for the liver disease MASH. Around 74% of adults in the trial taking the drug were free of MASH after 52 weeks, compared to approximately 13% of the placebo group.

MASH, formerly known as NASH, is a liver disease characterized by excess fat and inflammation. The chronic inflammation can also lead to liver scarring, or fibrosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Vertex cell therapy lets patients with type 1 diabetes stop insulin

WSS

The battle over 'scope creep' and who gets to be called 'doctor'

CDC Director Mandy Cohen on transparency, trust, and health

Dems pitch expanding Medicare power to negotiate drug prices

The haunting brain science of long Covid

'Screen and refer' systems are hurting patients

A letter from the executive editor: The 2023 STATUS List

explore

focus

entertainment

Peter Hotez and the public health issue of online harassment

'Investigate these claims': UFO transparency at center of House hearing

Novavax promises a turnaround & Lilly roils the obesity market

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

How to save PrEP access — and even expand it

STAT Report: Patient voices and perspectives

Continuity nursing helped my family in our darkest PICU moments

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Alkermes shareholders re

A letter from the executive editor: The 2023 STATUS List

Wikipedia

UpToDate has a racism problem: Dr. Stanley Goldfarb

Roche’s Alnylam deal shows drug firms interested in heart drugs

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Vertex cell therapy lets patients with type 1 diabetes stop insulin

Truvian presents data for its desktop blood

Dems pitch expanding Medicare power to negotiate drug prices

focus

knowledge

explore

leisure time